Haemonetics Corporation (NYSE:HAE) reported upbeat earnings for its third quarter on Thursday.The company posted quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.25 per share. The company reported quarterly sales of $338.967 million which beat the analyst consensus estimate of $331.616 million.Haemonetics raised its FY2026 adjusted EPS guidance from $4.80-$5.00 to $4.90-$5.00.Haemonetics shares fell 6% to trade at $61.13 on Friday.These analysts made changes to their pri ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...

Key Takeaways HAE delivered Q3 adjusted EPS of $1.31, up 10.1% y/y, while revenues fell 2.7% to $339M, yet beat estimates.HAE saw Plasma sales rise, while Blood Center and Hospital sales fell on order timing and portfolio cuts. Haemonetics expanded gross margin to 59.7% and operating margin to 23.3% as costs fell and profits rose. Haemonetics Corporation (HAE) delivered third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, which rose 10.1% year over year. The bottom line topped the Zacks Con ...

Haemonetics (NYSE:HAE) Q3 2026 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsAndrew Cooper - DirectorAnthony Petrone - Managing Director of Equity ResearchChris Simon - President and CEOJames D'Arecca - CFOJoanne Wuensch - Managing DirectorMarie Thibault - Managing DirectorOlga Guyette - VP of Investor Relations and TreasuryConference Call ParticipantsDavid Rescott - Senior Research AnalystMichael Petusky - Managing Director and Senior Research AnalystMike Matson - Senior AnalystRohin Pate ...

Haemonetics (NYSE:HAE) Q3 2026 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsAndrew Cooper - DirectorAnthony Petrone - Managing Director of Equity ResearchChris Simon - President and CEOJames D'Arecca - CFOJoanne Wuensch - Managing DirectorMarie Thibault - Managing DirectorOlga Guyette - VP of Investor Relations and TreasuryConference Call ParticipantsDavid Rescott - Senior Research AnalystMichael Petusky - Managing Director and Senior Research AnalystMike Matson - Senior AnalystRohin Pate ...

Haemonetics (NYSE:HAE) Q3 2026 Earnings call February 05, 2026 08:00 AM ET Speaker10Ladies and gentlemen, thank you for standing by, and welcome to the third quarter 2026 Hem, Haemonetics Corporation Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your ha ...

Core Insights - Haemonetics reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.19 per share a year ago [1] - The company achieved a revenue of $338.97 million for the quarter, surpassing the Zacks Consensus Estimate by 1.44%, although this represents a decline from $348.54 million in the same quarter last year [3] Earnings Performance - The earnings surprise for the recent quarter was +3.15%, following a previous surprise of +13.39% when earnings were $1.27 per share against an expectation of $1.12 per share [2] - Haemonetics has consistently surpassed consensus EPS estimates over the last four quarters [2] Stock Performance and Outlook - Haemonetics shares have declined approximately 17.7% since the beginning of the year, contrasting with a 0.5% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $1.30, with expected revenues of $334.48 million, and for the current fiscal year, the estimate is $4.93 on $1.32 billion in revenues [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which may impact Haemonetics' future performance [6]

Third Quarter Fiscal 2026 Results February 5, 2026 © 2026 Haemonetics Corporation Q3 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on February 5, 2026, and can be accessed via live webcast: Link or teleconference: Link. The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com. Conference call speakers: Chris Simon President & CEO James D'Arecca EVP, Chief Financial Officer Olga Gu ...

For the quarterly period ended: December 27, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2026 Results; Raises Total Company Fiscal 2026 Guidance Boston, MA, February 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial result ...